Type
|
Public |
---|---|
Traded as | NYSE: CRY S&P 600 Component |
Founded | 1984 |
Founder | Steve Anderson |
Headquarters | Kennesaw, Georgia, United States |
Key people
|
J. Patrick Mackin, Chairman of the Board, President & CEO |
Products | human tissues for transplant, medical devices |
Revenue | $146 million (2015) |
Number of employees
|
435 (2008) |
Website | www |
CryoLife, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
CryoLife, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist primarily of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010.
The Company preserves small diameter human saphenous vein conduits (3mm to 6mm) for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient. When patients require bypass surgery, the surgeon’s first choice generally is the patient’s own vein tissue. However, in cases of advanced vascular disease, 30% of patients have unsuitable vein tissue for transplantation, and the surgeon must consider using synthetic grafts or preserved human vascular tissue. Small diameter synthetic vascular grafts are generally not optimal for below-the-knee surgeries because they have a tendency to obstruct over time. Preserved human vascular tissues tend to remain open longer and as such are used in indications where synthetics typically fail. In addition, synthetic grafts are not suitable for use in infected areas since they may harbor bacteria and are difficult to treat with antibiotics. Preserved human vascular tissues are ideal grafts for patients with previously infected graft sites. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass or reconstruction within infected surgical areas.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2021 | 2022-02-09 | Future report Set alerts | |
Q3 2021 | 2021-11-04 | 0.26 | 0.26 |
Q2 2021 | 2021-07-29 | -0.06 | -0.06 |
Q1 2021 | 2021-04-29 | 0.03 | 0.03 |
Q4 2020 | 2021-02-11 | 0.20 | 0.20 |
Q3 2020 | 2020-11-04 | 0.13 | -0.08 |
Q2 2020 | 2020-07-30 | -0.02 | -0.10 |
Q1 2020 | 2020-04-30 | -0.08 | -0.18 |
Q4 2019 | 2020-02-13 | 0.10 | -0.02 |
Q3 2019 | 2019-10-30 | 0.06 | 0.00 |
2016-06-20 | Reiterated Rating | Canaccord Genuity | Buy | |
2016-06-15 | Initiated Coverage | Lake Street Capital | Buy | $15.00 |
2016-04-28 | Downgrade | Ladenburg Thalmann | Buy to Neutral | $12.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $15.00 |
2016-04-13 | Initiated Coverage | Canaccord Genuity | Buy | $14.00 |
2015-12-30 | Reiterated Rating | Piper Jaffray | Buy | |
2015-12-24 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
2015-05-18 | Initiated Coverage | First Analysis | Overweight | $14.00 |
2015-01-02 | Upgrade | Piper Jaffray | Neutral to Overweight | $15.00 |
2014-12-23 | Upgrade | Piper Jaffray | Neutral to Overweight | $10.00 to $15.00 |
2012-04-24 | Initiated | Ladenburg Thalmann | Buy | $7.75 |
2011-07-29 | Upgrade | The Benchmark Company | Hold to Buy | $6.50 |
2011-04-29 | Downgrade | The Benchmark Company | Buy to Hold | $7 to $6.50 |
2010-07-23 | Initiated | The Benchmark Company | Buy | $8 |
2008-08-01 | Reiterated | Jesup & Lamont | Buy | $14 to $16.50 |
2008-05-15 | Reiterated | Roth Capital | Buy | $12 to $14 |
2008-03-31 | Initiated | Roth Capital | Buy | $12 |
2008-03-18 | Initiated | Jesup & Lamont | Buy | $14 |
2007-05-02 | Upgrade | Piper Jaffray | Market Perform to Outperform |
2016-06-20 | Reiterated Rating | Canaccord Genuity | Buy | |
2016-06-15 | Initiated Coverage | Lake Street Capital | Buy | $15.00 |
2016-04-28 | Downgrade | Ladenburg Thalmann | Buy to Neutral | $12.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $15.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CRY 123 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 7.24M |
Vanguard Group, Inc | 2.75M |
MACQUARIE GROUP LTD | 2.59M |
BlackRock Fund Advisors | 2.37M |
WASATCH ADVISORS INC | 2.13M |
MORGAN STANLEY | 1.97M |
STATE STREET CORP | 1.56M |
DIMENSIONAL FUND ADVISORS LP | 1.44M |
KILLEN GROUP INC | 1.42M |
WELLINGTON MANAGEMENT CO LLP | 1.40M |
GANNETT WELSH & KOTLER | 1.36M |
PERCEPTIVE ADVISORS LLC | 1.20M |
ROYCE & ASSOCIATES LLC | 0.92M |
BlackRock Institutional Trust Company, N.A. | 0.77M |
GEODE CAPITAL MANAGEMENT, LLC | 0.67M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
ANDERSON STEVEN G President, CEO and Chairman | 4.55% (1271846) | CRY / |
Mackin James P President & CEO | 1.26% (351095) | CRY / |
LEE DAVID ASHLEY Exec. VP, COO and CFO | 1.07% (300079) | CRY / |
McCall Ronald D | 0.52% (146511) | CRY / |
Capps Scott B VP-Clinical Research | 0.50% (139087) | CRY / |
FRONK DAVID VP Reg. Affrs. and Qual Assur. | 0.40% (110559) | CRY / |
Horton Amy Chief Accounting Officer | 0.37% (102959) | CRY / |
ACKERMAN THOMAS F | 0.36% (99349) | CRL / CRY / |
BEVEVINO DANIEL J | 0.36% (99349) | CRY / |
RONALD C ELKINS | 0.35% (97849) | CRY / |
Burris Jeffrey W Vice President & Gen. Counsel | 0.34% (95221) | CRY / |
Salveson Jon W | 0.28% (79349) | CRY / SSH / |
Gale David C VP-Research and Development | 0.28% (77135) | CRY / |
Lang David P. Sr. VP, Intl Sales & Marketing | 0.25% (68441) | CRY / |
Holloway Jean F VP, General Counsel | 0.21% (57877) | CRY / |
Benson James | 0.19% (54086) | CRY / |
Davis John E Senior VP, Global Sales | 0.18% (51438) | CRY / |
Anderson Bruce G. VP, US Sales and Marketing | 0.15% (42106) | CRY / |
MORGAN HARVEY | 0.15% (40667) | CRY / CYB / FDO / |
Matthews William Robert Senior VP, Operations, Quality | 0.14% (39883) | CRY / |
McDermid James M SVP, CHRO | 0.08% (21339) | CRY / |
Bullock James | 0.03% (8266) | CRY / |
Saurini Sherry M VP, Quality | 0.02% (5294) | CRY / |